FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081020277> ?p ?o ?g. }

• W3081020277 endingPage "1274" @default.
• W3081020277 startingPage "1264" @default.
• W3081020277 abstract "Aim To optimize the therapeutic strategy for cirrhotic patients manifesting hepatic encephalopathy, factors affecting the outcome of patients receiving rifaximin were evaluated. Methods The subjects were 95 patients receiving rifaximin. Serum ammonia levels were measured serially during rifaximin treatment. Factors associated with long‐term outcomes and cumulative survival rates were evaluated. Results Serum ammonia levels were decreased at 4 weeks after rifaximin treatment compared to the levels at baseline even in patients receiving rifaximin as an add‐on therapy with lactitol hydrate ( P < 0.001) and reduction values were negatively correlated with the maximal diameter of portosystemic shunts (r = −0.275, P = 0.009). Overt encephalopathy occurred in 37 patients (38.9%) during rifaximin treatment, and the hazard function analysis identified 90 days as a high‐risk term for developing the first‐time overt encephalopathy. Thus, the long‐term outcome was judged as favorable in 77 patients (81.1%) in whom overt encephalopathy was absent for at least 90 days during rifaximin initiation. A multivariate analysis revealed that furosemide, especially at daily doses of ≥20 mg both at baseline and during rifaximin treatment, was a significant factor associated with unfavorable outcome ( P = 0.009 and P = 0.022, respectively) as well as occurrence and recurrence of overt encephalopathy ( P = 0.012). Moreover, furosemide treatment significantly deteriorated the cumulative survival rate of patients receiving rifaximin ( P = 0.026). Conclusion Furosemide contributed to the deteriorated outcome of patients receiving rifaximin. Consequently, rifaximin should be given before increasing the furosemide dose, and the furosemide dose should not be increased during rifaximin treatment." @default.
• W3081020277 created "2020-09-01" @default.
• W3081020277 creator A5010716671 @default.
• W3081020277 creator A5025979180 @default.
• W3081020277 creator A5028178304 @default.
• W3081020277 creator A5028598605 @default.
• W3081020277 creator A5032681093 @default.
• W3081020277 creator A5036436319 @default.
• W3081020277 creator A5036815639 @default.
• W3081020277 creator A5049322774 @default.
• W3081020277 creator A5059237008 @default.
• W3081020277 creator A5072731275 @default.
• W3081020277 creator A5074285891 @default.
• W3081020277 creator A5087133884 @default.
• W3081020277 date "2020-09-26" @default.
• W3081020277 modified "2023-09-26" @default.
• W3081020277 title "Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis" @default.
• W3081020277 cites W1862726000 @default.
• W3081020277 cites W1964051982 @default.
• W3081020277 cites W1979124801 @default.
• W3081020277 cites W2003796334 @default.
• W3081020277 cites W2011340962 @default.
• W3081020277 cites W2026317976 @default.
• W3081020277 cites W2071256462 @default.
• W3081020277 cites W2091958019 @default.
• W3081020277 cites W2099360240 @default.
• W3081020277 cites W2105932465 @default.
• W3081020277 cites W2122600418 @default.
• W3081020277 cites W2165692198 @default.
• W3081020277 cites W2416980505 @default.
• W3081020277 cites W2470715145 @default.
• W3081020277 cites W2524364594 @default.
• W3081020277 cites W2592541035 @default.
• W3081020277 cites W2771590345 @default.
• W3081020277 cites W2774313276 @default.
• W3081020277 cites W2783985141 @default.
• W3081020277 cites W2791786258 @default.
• W3081020277 cites W2914813452 @default.
• W3081020277 cites W2953896279 @default.
• W3081020277 cites W2965382573 @default.
• W3081020277 cites W3013226060 @default.
• W3081020277 cites W3016266178 @default.
• W3081020277 doi "https://doi.org/10.1111/hepr.13564" @default.
• W3081020277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32886950" @default.
• W3081020277 hasPublicationYear "2020" @default.
• W3081020277 type Work @default.
• W3081020277 sameAs 3081020277 @default.
• W3081020277 citedByCount "2" @default.
• W3081020277 countsByYear W30810202772022 @default.
• W3081020277 countsByYear W30810202772023 @default.
• W3081020277 crossrefType "journal-article" @default.
• W3081020277 hasAuthorship W3081020277A5010716671 @default.
• W3081020277 hasAuthorship W3081020277A5025979180 @default.
• W3081020277 hasAuthorship W3081020277A5028178304 @default.
• W3081020277 hasAuthorship W3081020277A5028598605 @default.
• W3081020277 hasAuthorship W3081020277A5032681093 @default.
• W3081020277 hasAuthorship W3081020277A5036436319 @default.
• W3081020277 hasAuthorship W3081020277A5036815639 @default.
• W3081020277 hasAuthorship W3081020277A5049322774 @default.
• W3081020277 hasAuthorship W3081020277A5059237008 @default.
• W3081020277 hasAuthorship W3081020277A5072731275 @default.
• W3081020277 hasAuthorship W3081020277A5074285891 @default.
• W3081020277 hasAuthorship W3081020277A5087133884 @default.
• W3081020277 hasConcept C126322002 @default.
• W3081020277 hasConcept C207103383 @default.
• W3081020277 hasConcept C2777214474 @default.
• W3081020277 hasConcept C2777955127 @default.
• W3081020277 hasConcept C2778621155 @default.
• W3081020277 hasConcept C2778889925 @default.
• W3081020277 hasConcept C2780325230 @default.
• W3081020277 hasConcept C2780496750 @default.
• W3081020277 hasConcept C2781099255 @default.
• W3081020277 hasConcept C44249647 @default.
• W3081020277 hasConcept C501593827 @default.
• W3081020277 hasConcept C71924100 @default.
• W3081020277 hasConcept C86803240 @default.
• W3081020277 hasConcept C89423630 @default.
• W3081020277 hasConcept C90924648 @default.
• W3081020277 hasConceptScore W3081020277C126322002 @default.
• W3081020277 hasConceptScore W3081020277C207103383 @default.
• W3081020277 hasConceptScore W3081020277C2777214474 @default.
• W3081020277 hasConceptScore W3081020277C2777955127 @default.
• W3081020277 hasConceptScore W3081020277C2778621155 @default.
• W3081020277 hasConceptScore W3081020277C2778889925 @default.
• W3081020277 hasConceptScore W3081020277C2780325230 @default.
• W3081020277 hasConceptScore W3081020277C2780496750 @default.
• W3081020277 hasConceptScore W3081020277C2781099255 @default.
• W3081020277 hasConceptScore W3081020277C44249647 @default.
• W3081020277 hasConceptScore W3081020277C501593827 @default.
• W3081020277 hasConceptScore W3081020277C71924100 @default.
• W3081020277 hasConceptScore W3081020277C86803240 @default.
• W3081020277 hasConceptScore W3081020277C89423630 @default.
• W3081020277 hasConceptScore W3081020277C90924648 @default.
• W3081020277 hasIssue "11" @default.
• W3081020277 hasLocation W30810202771 @default.
• W3081020277 hasLocation W30810202772 @default.
• W3081020277 hasOpenAccess W3081020277 @default.
• W3081020277 hasPrimaryLocation W30810202771 @default.

• next